Apixaban and Cilostazol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Apixaban (apixaban) and Cilostazol (cilostazol). Common drug interactions include cardiac failure congestive among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Apixaban and Cilostazol. It is created by eHealthMe based on reports of 48 people who take the same drugs from the FDA, and is updated regularly.

What is Apixaban?

Apixaban has active ingredients of apixaban. It is often used in blood clots. eHealthMe is studying from 60,351 Apixaban users. Check the latest studies of Apixaban.

What is Cilostazol?

Cilostazol has active ingredients of cilostazol. It is often used in arteriosclerosis of the extremities. eHealthMe is studying from 7,877 Cilostazol users. Check the latest studies of Cilostazol.



On Jul, 21, 2026

48 people who take Apixaban and Cilostazol together, and have interactions are studied.

Apixaban and Cilostazol drug interactions.

What are the common drug interactions of Apixaban and Cilostazol, by gender? *:

female:

  1. Cardiac failure congestive
  2. Abdominal wall haematoma (abdominal wall blood clotting)
  3. Cerebral infarction (less blood supply to brain resulting tissue damage)
  4. Chronic kidney disease
  5. Diabetes mellitus inadequate control
  6. Gastritis haemorrhagic (inflammation of stomach with bleeding)
  7. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  8. Hypotension (abnormally low blood pressure)
  9. Intra-abdominal haemorrhage (intra-abdominal bleeding)
  10. Iron deficiency anaemia

male:

  1. Pneumonia
  2. Cardiac arrest
  3. Haematochezia (passage of stools containing blood)
  4. Hypoglycaemia (deficiency of glucose in the bloodstream)
  5. Hypokalaemia (low potassium)
  6. Ilium fracture
  7. Pleural effusion (water on the lungs)
  8. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  9. Sinus tachycardia (a heart rhythm with elevated rate of impulses originating from the sinoatrial node)
  10. Spinal compression fracture (fracture due to spinal compression on bone)

What are the common drug interactions of Apixaban and Cilostazol, by age (0-1 to 60+)? *:

0-1:

  1. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  2. Hypotension (abnormally low blood pressure)
  3. Tachycardia (a heart rate that exceeds the range of 100 beats/min)

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Peripheral arterial occlusive disease (reproducible ischemic muscle pain)
  2. Abdominal wall haematoma (abdominal wall blood clotting)
  3. Intra-abdominal haemorrhage (intra-abdominal bleeding)

60+:

  1. Pneumonia
  2. Cardiac arrest
  3. Haematochezia (passage of stools containing blood)
  4. Hypoglycaemia (deficiency of glucose in the bloodstream)
  5. Hypokalaemia (low potassium)
  6. Ilium fracture
  7. Pleural effusion (water on the lungs)
  8. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  9. Sinus tachycardia (a heart rhythm with elevated rate of impulses originating from the sinoatrial node)
  10. Spinal compression fracture (fracture due to spinal compression on bone)

What are the existing conditions these people have? *

  1. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 13 people, 27.08%
  2. High Blood Pressure: 12 people, 25.00%
  3. Diabetes: 7 people, 14.58%
  4. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 5 people, 10.42%
  5. Cardiac Failure: 5 people, 10.42%
  6. Peripheral Arterial Occlusive Disease (reproducible ischemic muscle pain): 5 people, 10.42%
  7. Type 2 Diabetes: 4 people, 8.33%
  8. Multiple Myeloma (cancer of the plasma cells): 4 people, 8.33%
  9. Constipation: 4 people, 8.33%
  10. Dyslipidaemia (abnormal amount of lipids): 4 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Apixaban and Cilostazol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Apixaban and Cilostazol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Apixaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Cilostazol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Apixaban and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cilostazol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on apixaban and cilostazol (the active ingredients of Apixaban and Cilostazol, respectively), and Apixaban and Cilostazol (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: